高能量聚焦超声治疗放疗后复发前列腺癌:一项北美临床试验
该开放标签试验于2009至2012年在16个中心(美国14个、加拿大2个)纳入100例体外放疗后至少2年临床局限复发前列腺癌男性,行全腺体高能量聚焦超声,主要终点为12个月PSA最低值≤0.5 ng/ml且活检阴性,结果50例达到该终点,结论认为该治疗看似合理安全有效。
要点
- 100例中78例完成12个月活检,其中63例(81%)活检阴性。
- 主要终点PSA最低值≤0.5 ng/ml且活检阴性在50例中达到。
- 91例发生不良事件,CTCAE 3级20例,包括直肠瘘5例(3例需手术)、耻骨骨炎3例、需干预血尿3例。
核心结论
- 全腺体高能量聚焦超声治疗放疗后复发前列腺癌看似合理安全有效。
- 并发症可能严重但发生率可接受,尤其考虑到疾病晚期难治且治疗选择有限。
研究设计与样本
- 开放标签试验,2009至2012年纳入100例体外放疗后至少2年临床局限复发前列腺癌男性。
- 治疗在16个中心进行,包括美国14个和加拿大2个。
- 主要终点为12个月前列腺特异性抗原最低值≤0.5 ng/ml且活检阴性。
主要发现
- 100例接受治疗男性平均年龄70岁(范围53至83),78例完成12个月活检,其中63例(81%)阴性。
- 平均前列腺特异性抗原4.9 ng/ml(范围0.4至14),Gleason评分中位数7。
- 主要终点PSA最低值≤0.5 ng/ml且活检阴性在50例中达到。
- 试验后随访中,33例患者2年平均前列腺特异性抗原为1.1 ng/ml(范围0.1至17)。
- 12个月内91例发生不良事件,CTCAE 1级67例、2级80例、3级20例。
临床怎么用
- 原研究结论认为全腺体高能量聚焦超声治疗放疗后复发前列腺癌看似合理安全有效,并发症可能严重但发生率可接受。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We determined the safety and efficacy of whole gland high intensity focused ultrasound in men with radiorecurrent prostate cancer. MATERIALS AND METHODS: A total of 100 men with clinically localized recurrent prostate cancer at least 2 years after external beam radiation therapy underwent whole gland high intensity focused ultrasound in an open label trial from 2009 to 2012. Treatments were performed at 16 sites, including 14 in the United States and 2 in Canada. The primary end point was the combination of a prostate specific antigen nadir of 0.5 ng/ml or less and negative biopsy at 12 months. Validated questionnaires were administered to monitor changes in urinary and sexual function. RESULTS: Of the 100 treated men, in whom mean age was 70 years (range 53 to 83), 78 completed the 12-month biopsy, which was negative in 63 (81%). Mean prostate specific antigen was 4.9 ng/ml (range 0.4 to 14) and the median Gleason score was 7. The 1-year end point of a prostate specific antigen nadir of 0.5 ng/ml or less plus negative biopsy was achieved in 50 men. During post-trial followup mean prostate specific antigen at 2 years was 1.1 ng/ml (range 0.1 to 17) in 33 patients. Adverse events developed in 91 men through 12 months, which were CTCAE grade 1 in 67, grade 2 in 80 and grade 3 in 20. Treatment related grade 3 adverse events included rectal fistulas in 5 men, which required surgery in 3, osteitis pubis in 3 and hematuria requiring intervention in 3. Treatment related grade 3 adverse events developed early in the trial and appeared related to operator experience. There were no life threatening adverse events or treatment related deaths. CONCLUSIONS: Whole gland high intensity focused ultrasound appears reasonably safe and effective to treat radiorecurrent prostate cancer. The rate of complications, which are potentially severe, was acceptable, especially considering the advanced, refractory nature of the disease and the limited treatment options.
引用
- Jones TA, Chin J, Mcleod D, et al. High Intensity Focused Ultrasound for Radiorecurrent Prostate Cancer: A North American Clinical Trial. J Urol. 2017. PMID: 28652121. doi:10.1016/j.juro.2017.06.078
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。